The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Specifying which patients should undergo cardiovascular surveillance following lymphoma treatment
Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses the evolving landscape of cardiovascular surveillance in patients undergoing lymphoma treatment. He emphasizes the need for individualized approaches due to limited data on specific surveillance protocols tailored to each therapy. Dr Svoboda highlights the need for further research into therapies such as BTK inhibitors, immune checkpoint inhibitors, and CAR-T therapies to better understand their cardiovascular implications. This interview occurred at the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role: Adaptive Biotechnologies; AstraZeneca; Atara Biotherapeutics; BMS; Crispr therapeutics; Pharmacyclics; Seagen. Research Funding: Adaptive Biotechnologies (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Kite, a Gilead company (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst).
